RxDoctor Payments Data

Nabil Khalil, MD

General Practice · Los Angeles, CANPI 1649387879

Payments from drug & device makers

$1,025in general payments, 2019–2025

Across 28 payments — averaging $36.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$300
  • Redhill Biopharma Inc.$282
  • Lilly USA, LLC$200
  • Novo Nordisk$122
  • Exact Sciences$53
  • Cranial Technologies, Inc$34
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$1,025100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,025 in reported general payments places this provider in the 80th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$16,382
Medicare patients
42
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$31,235
JanuviaSitagliptin Phosphate36$28,122
JardianceEmpagliflozin22$12,891
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm35$2,671
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm13$2,033
Comfort Ez Insulin SyringeSyringe-Needle,insulin,0.5 Ml18$1,826
Atorvastatin Calcium233$1,736
Albuterol Sulfate HfaAlbuterol Sulfate65$1,699
Ondansetron Hcl33$1,591
Gabapentin87$1,297
Comfort Ez Pen NeedlePen Needle, Diabetic14$1,224
Ventolin HfaAlbuterol Sulfate12$1,010
Metformin Hcl213$984
Alcohol PadsAlcohol Antiseptic Pads48$883
Losartan Potassium131$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$122$31,23534 claims
MerckJanuvia$19$28,12236 claims
Lilly USA, LLCHumulin 70-30$200$2,67135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 12,963 general practice providers in California.

Other general practice in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →